RxDoctor Payments Data

Rafael Rosa-Algarin, MD

General Practice · Ocala, FLNPI 1740482520

Payments from drug & device makers

$1,094in general payments, 2019–2025

Across 17 payments — averaging $64.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$565
  • Stryker$174
  • Amgen$138
  • Bayer$124
  • AbbVie$31
  • Philips North America LLC$19
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$1,094100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,094 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$309,264
Medicare patients
345
Services billed
9,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$77,530
EliquisApixaban21$33,183
OzempicSemaglutide20$25,771
XareltoRivaroxaban19$23,229
SymbicortBudesonide/Formoterol Fumarate16$4,189
SynthroidLevothyroxine Sodium41$3,779
Gabapentin96$2,614
Omega-3 Acid Ethyl Esters28$2,608
Atorvastatin Calcium307$2,566
Omeprazole126$2,505
Levothyroxine Sodium216$2,309
Duloxetine Hcl41$1,502
Rosuvastatin Calcium144$1,440
Humalog Kwikpen U-100Insulin Lispro11$1,415
Lisinopril187$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$25,77120 claims
Johnson & JohnsonXarelto$565$23,22919 claims
AbbVieSynthroid$31$3,77941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.

Other general practice in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →